A vaccine developed by Moderna in the USA has shown promising results as expected, various news sources have reported.
Bloomberg stated that the shot would move into the final stages of testing later this month after boosting the immune systems of all patients tested.
The vaccine created a vigorous immune response
“Well, they’re in phase one studies, but it’s a good step,” Dr William Schaffner from the Vanderbilt University told Bloomberg, “it looks as though the vaccines generated a vigorous immune response. We like that. We think that’s going to be associated with protection.”
However, Dr Schaffner stated that two things emerged from the vaccine;
One, that the vaccine was a two-dose vaccine. Two, there were some side effects, such as the patients developing sore arms and feeling a little feverish and fatigued.
Nonetheless, he said there was nothing in the side effects that would inhibit them from going forward to a larger trial.
Additionally, he said that this was a small price to pay for protection against COVID-19.
The results were from the first 45 people who received the shot.
Moderna's Covid-19 vaccine produced antibodies to the coronavirus in all patients tested in an initial safety trial, federal researchers say.
— Bloomberg (@business) July 15, 2020
The next and final stage of the vaccine tests would then compare the vaccine to placebo shots administered to 30,000 healthy people who are at high risk of going down with COVID-19.
The comparisons were to ensure the vaccine works in people who are vulnerable, as they are the ones who need protection the most from COVID-19.
The vaccine was a collaboration between Moderna and National Institute of Health in the US.
Kenya not far behind
Back here in Kenya, KEMRI has also been working on developing a vaccine. The researchers would develop one to work on the virus strain in the country.
The news comes hot in the heels of the WHO developing a program to ensure equitable distribution of vaccines. COVAX, the program, was a collaboration between WHO, CEPI and GAVI.